Abdulwahid Dhurgham A, Hassan Mea'ad K
Department of Pediatrics, Basra Maternity and Children Hospital , Barsa , Iraq.
Hemoglobin. 2013;37(6):553-63. doi: 10.3109/03630269.2013.825841. Epub 2013 Aug 15.
Hemoglobinopathies are common in Iraq and β-thalassemia major (β-TM) is a leading health problem in Basra, Southern Iraq. However, β- and α-thalassemia intermedia (β- and α-TI) have not been so well studied. This is a descriptive study of 152 consecutive β- and α-TI patients registered at the Centre for Hereditary Blood Diseases (CHBD) in Basra, Southern Iraq from October 1 2010 through June 30 2012 including age at diagnosis, blood transfusions and complications. β-Thalassemia intermedia was found in 80 (52.6%) patients with a mean age at diagnosis of 7.10 ± 8.0 years. This was significantly different from that of Hb H (β4) disease (12.95 ± 14.8 years), p <0.05. Patients with β-TI received significantly more blood transfusions (3.39 ± 3.85)/year compared to those with Hb H disease (1.07 ± 1.39)/year, p <0.05. Short stature, extramedullary erythropoiesis, pulmonary hypertension and iron overload were significantly higher among patients with β-TI compared to those with Hb H disease, p <0.05. Iron overload is a significant risk factor for growth retardation among patients with Hb H and β-TI. While age is a significant risk factor for osteoporosis in both types of thalassemia intermedia. Both α- and β-thalassemia (α- and β-thal) have been reported in Basra. Although β-TI is associated with a more severe disease than α-TI, both are associated with considerable complications. Thus, genetic studies are needed to determine the types of mutation producing β-TI and the exact α-thal determinants producing Hb H disease as they are important in the prediction of the phenotype severity.
血红蛋白病在伊拉克很常见,重度β地中海贫血(β-TM)是伊拉克南部巴士拉的一个主要健康问题。然而,中间型β和α地中海贫血(β-TI和α-TI)尚未得到充分研究。这是一项描述性研究,对2010年10月1日至2012年6月30日在伊拉克南部巴士拉遗传性血液病中心(CHBD)登记的152例连续的β-TI和α-TI患者进行了研究,包括诊断年龄、输血情况和并发症。在80例(52.6%)患者中发现了中间型β地中海贫血,诊断时的平均年龄为7.10±8.0岁。这与血红蛋白H(β4)病(12.95±14.8岁)有显著差异,p<0.05。与血红蛋白H病患者(每年1.07±1.39次)相比,β-TI患者每年接受的输血次数明显更多(3.39±3.85次),p<0.05。与血红蛋白H病患者相比,β-TI患者的身材矮小率、髓外造血、肺动脉高压和铁过载明显更高,p<0.05。铁过载是血红蛋白H病和β-TI患者生长发育迟缓的一个重要危险因素。而年龄是两种中间型地中海贫血患者骨质疏松的一个重要危险因素。巴士拉已报告了α和β地中海贫血(α-TI和β-TI)。虽然β-TI比α-TI与更严重的疾病相关,但两者都与相当多的并发症相关。因此,需要进行基因研究来确定产生β-TI的突变类型以及产生血红蛋白H病的确切α地中海贫血决定因素,因为它们在预测表型严重程度方面很重要。